Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
300267.SZ Stock Price Chart
Explore Hunan Er-Kang Pharmaceutical Co., Ltd interactive price chart. Choose custom timeframes to analyze 300267.SZ price movements and trends.
300267.SZ Company Profile
Discover essential business fundamentals and corporate details for Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
27 Sept 2011
Employees
1.50K
Website
https://www.hnerkang.comCEO
Qingrong Sun
Description
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate and its series products. The company was founded in 2003 and is based in Liuyang, China.
300267.SZ Financial Timeline
Browse a chronological timeline of Hunan Er-Kang Pharmaceutical Co., Ltd corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 16 May 2025
EPS came in at -¥0.17 , while revenue for the quarter reached ¥285.32M .
Earnings released on 31 Mar 2025
EPS came in at ¥0.01 , while revenue for the quarter reached ¥353.55M .
Earnings released on 29 Sept 2024
EPS came in at -¥0.02 , while revenue for the quarter reached ¥232.94M .
Earnings released on 30 Jun 2024
EPS came in at ¥0.00 , while revenue for the quarter reached ¥345.56M .
Earnings released on 17 May 2024
EPS came in at -¥0.11 , while revenue for the quarter reached ¥338.20M .
Earnings released on 31 Mar 2024
EPS came in at ¥0.00 , while revenue for the quarter reached ¥271.32M .
Earnings released on 30 Sept 2023
EPS came in at -¥0.01 , while revenue for the quarter reached ¥395.21M .
Earnings released on 30 Jun 2023
EPS came in at ¥0.01 , while revenue for the quarter reached ¥503.24M .
Dividend declared on 9 Jun 2023
A dividend of ¥0.03 per share was announced, adjusted to ¥0.03. The dividend was paid on 9 Jun 2023.
Earnings released on 31 Mar 2023
EPS came in at ¥0.01 , while revenue for the quarter reached ¥546.93M .
Earnings released on 1 Jan 2023
EPS came in at ¥0.00 , while revenue for the quarter reached ¥553.15M .
Earnings released on 30 Sept 2022
EPS came in at ¥0.00 , while revenue for the quarter reached ¥446.84M .
Earnings released on 30 Jun 2022
EPS came in at ¥0.00 , while revenue for the quarter reached ¥444.20M .
Earnings released on 29 Apr 2022
EPS came in at -¥0.46 , while revenue for the quarter reached ¥653.97M .
Earnings released on 31 Mar 2022
EPS came in at ¥0.01 , while revenue for the quarter reached ¥426.35M .
Earnings released on 30 Sept 2021
EPS came in at ¥0.03 , while revenue for the quarter reached ¥748.90M .
Earnings released on 30 Jun 2021
EPS came in at ¥0.02 , while revenue for the quarter reached ¥448.64M .
Dividend declared on 9 Jun 2021
A dividend of ¥0.05 per share was announced, adjusted to ¥0.05. The dividend was paid on 9 Jun 2021.
Earnings released on 31 Mar 2021
EPS came in at ¥0.03 , while revenue for the quarter reached ¥383.79M .
Earnings released on 31 Dec 2020
EPS came in at ¥0.01 , while revenue for the quarter reached ¥600.99M .
Earnings released on 30 Sept 2020
EPS came in at ¥0.06 , while revenue for the quarter reached ¥579.02M .
300267.SZ Stock Performance
Access detailed 300267.SZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.